Liposarcomas is the most common mesenchymal tumor of the retroperitoneal space but RPLS continues to pose a challenge with regards to diagnosis, prediction of clinical behavior, and treatment of disease recurrence within the intra-abdominal and retroperitoneal space. Retroperitoneal liposarcomas tend to be of low to intermediate grade, while other sarcomas of other histologic types e.g. leiomyosarcomas in this location tend to be high grade[4, 15, 16]. Sarcomas are believed to arise de novo, spreading by direct, local extension or hematogenous routes, metastases at the time of initial presentation are uncommon. However, if metastatic, the lungs are the most common site of initial metastases.
The two largest series to date on RPLS were published in the Western population by Neuhaus et al. and Singer et al., however, there is little data in the current literature describing RPLS in the Asian population[4, 16]. Histological grade was consistently reported to be the most important factor affecting survival rates for patients with liposarcomas[17]. In our series by comparing tumors that are grade 1 against grade 2 and 3 tumors, there was no statistical significance detected probably due to the limited sample size. The median tumor burden of 36 cm for our patients also appears to be larger than that reported in western literature[4].
There are two widely accepted grading systems internationally for soft tissue sarcomas, the National Cancer Institute (NCI) and the French Federation of Cancer Centres (FNCLCC) grading system. Both systems have proven to have prognostic value and share several features e.g. the emphasis on the histological type and the evaluation of the amount of necrosis. Neither of the systems is endorsed solely by the Association of Directors of Anatomic and Surgical Pathology or the WHO as yet[12, 18]. To further aid in risk stratification and prognostication, nomograms are becoming a popular tool; Memorial Sloan-Kettering has designed and validated their nomogram for 12-year sarcoma-specific mortality utilizing seven histological types as considerations to calculate the probability of a patient reaching a designated clinical end-point[19, 20]. Despite these problems, grading of sarcomas has been an important progress pathologists have contributed to the treatment of sarcomas. Grading identifies patients at highest risk of distant metastasis and aggressive tumor behavior, thus helps and guides oncologists in the management of these patients.
From the literature, the overall 5-year survival for well-differentiated subtypes is 90%, while 5-year survival for pleomorphic subtypes is only 30-50%. De-differentiated and myxoid/round cell subtypes have intermediate 5-year survival rates of 75% and 60-90%, respectively. Well-differentiated liposarcomas may recur locally, but metastatic potential is low. Pleomorphic liposarcomas have high metastatic potential, accounting for the decreased rate of survival[4]. It been reported recently that well differentiated liposarcomas and de-differentiated liposarcomas have different biological behaviors, in de-differentiated tumors, they tend to present as a recurrence more often, require multi-organ resection more frequently and has a shorter disease free interval when compared to well differentiated subtypes[21]. In our series, out of the 11 patients with recurrence, all of them had loco-regional recurrence and the majority of them have well differentiated subtypes (n = 7, 64%) with only one patient with concurrent liver metastases. Our aggressive surgical policy of achieving gross negative margins including contiguous organ resection if necessary have resulted in comparable survival rates despite the median tumor burden larger compared to the western literature.
In the literature, factors with negative prognostic value regarding survival include de-differentiation subtype, grade 2-3, stage II-III, size >20 cm, and involved surgical margins[4]. In our series, some of these factors also showed a negative prognostic trend although it did not reach any statistical significance. The retroperitoneal location is a negative prognostic factor and a significant risk factor when considering local recurrence of disease. Distant metastasis is more common with de-differentiation, grade II-III, and deep seated location[17]. Distant metastasis also relates to tumor size. In a review of 460 patients with liposarcoma of which 35% are RPLS (n = 159) who had achieved local control of their disease, recurrence and incidence of metastatic disease at 5 years was noted to increase significantly with increased tumor size at initial evaluation[22]. The RPLS is of special interest as the retroperitoneum is the second most common site of occurrence, with up to 36% of liposarcomas occurring at this site. The tumor is often deep-seated and large at the time of diagnosis as the retroperitoneum space provides a large potential volume allowing sizeable growth prior to development of signs and symptoms[4, 17]. In our series, consistent with the current literature, we found that the presence of contiguous organ resection and tumor size of greater than 20 cm was negatively associated with prognosis, although due to a small sample size, there was no statistical significance detected. The mainstay of treatment is complete surgical resection. Complete resection was often challenging as the tumor may be difficult to distinguish from normal retroperitoneal fat. Furthermore, adjacent organs involved by the tumor may also need to be resected[4]. Failure to achieve macroscopic clearance was often due to the size of the tumor and the need for extensive visceral resection. Retroperitoneal liposarcomas is often large at presentation and can grow to enormous size, weighing over 100 pounds and measuring 50 cm in maximum diameter[23]. The largest tumor diameter in our series was 43 cm, with almost half of the tumors measuring more than 20 cm (42.9%). Studies had shown that complete resection may increase overall 5-year survival to 58% from 16.7%[17]. These tumors usually arise from the perinephric fat and as a result, kidney involvement was not unexpected, they often displaced the kidney peripherally or caused the kidney to be rotated away and in advanced cases the tumor may encase the kidney or cause pelvi-ureteric obstruction. Kidney was the most common organ resected followed by the colon and this was shown in our series as well. In a palliative setting, the colon was the organ most commonly resected followed by the kidney[16]. Notably, our series has a high rate of contiguous organ resection as compared to some earlier larger western series [4] (76% vs. 26%), this is mostly likely attributed by the larger tumor burden of our patients but our percentage of achieving negative microscopic margins is comparable to centres that advocate extensive resections[24, 25]. We postulate that this is in part due to the later presentation of our Asian patients to tertiary healthcare[26, 27]. This delay in presentation may be contributed by the cultural preference of our patients to seek traditional medical care over western medicine and the general reluctance of patients to obtain early medical attention for their symptoms, tending to ignore even significant symptoms till the disease is incapacitating or when family members coax and brings the patient to see a doctor The level of general medical knowledge is also poorer in the older generation in many Asian societies as compared to their Western counterparts. However in the recent years, as we understand that positive margins were associated with decreased survival, extensive or wide resection e.g. compartmental resections have been shown and advocated, to be performed especially in high volume tertiary centres, to achieve better outcomes[24, 25].
There is no strong evidence that chemotherapy or radiotherapy is curative[28, 29]. There is no prospective randomized controlled trial confirming the potential benefit of radiotherapy that emerges from retrospective studies[11, 30]. Given the large size and truncal location of retroperitoneal liposarcomas, adjuvant radiation is often not an option secondary to substantial morbidity associated with the required radiation doses and fields. Similarly, in well-differentiated low grade tumors, adjuvant chemotherapy yields little benefit. In high-grade disease, administration of adriamycin and ifosfamide may yield partial responses in up to 50% of patients with increased overall survival; however, complete responses are seen in less than 10% of patients[11]. To date, there are few prospective clinical trials analyzing chemo-radiotherapy regimes for retroperitoneal sarcomas, there is none specific and solely for retroperitoneal liposarcoma histological subtype[11, 30]. Retroperitoneal recurrences are often difficult to control, with death most often occurring from local effects of the tumor burden[17].. Despite an aggressive surgical approach, in our series we only achieve 5 year OS of 49%, this is probably in part attributed to the poor efficacy of neoadjuvant and adjuvant therapies. As such, the biology and molecular alteration of this disease need to be further characterized with more basic and translational research to explore new, innovative targeted therapeutic agents that target specific translocation or amplification products, this approach forward may offer promise for this rare and lethal disease[31].
As RPLS is a rare entity, a multi-institution prospective database will serve well to understand this disease more comprehensively. The limitations of our study is that the review is retrospective in nature and thus prone to bias, due to the limited sample size, there will be a element of type II error, resulting in a difficulty of achieving firm conclusion and statistical significance with regards to the prognostic factors analysis.